论文信息 - Guidelines for the diagnosis and treatment of pulmonary hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Guidelines and Expert Consensus Documents summarise and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (http://www.escardio.org/knowledge/guidelines). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. Unpublished clinical trial results are not taken into account. A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk/benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in tables 1⇓ and 2⇓. The experts of the writing panels have provided disclosure statements of all relationships they may have which might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must …

[1] H. Marshall,et al. Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension , 2012, European Radiology.

[2] S. Ley,et al. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH) , 2012, European Radiology.

[3] Shengshou Hu,et al. Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis , 2011, Cardiology.

[4] V. Russo,et al. Extensive right pulmonary artery dissection in a young patient with chronic pulmonary hypertension , 2011, Heart.

[5] Nico Westerhof,et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[6] J. Granton,et al. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. , 2011, American journal of respiratory and critical care medicine.

[7] M. Humbert,et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. , 2011, Arthritis and rheumatism.

[8] A. Klein,et al. Extracorporeal membrane oxygenation as a bridge to pulmonary endarterectomy. , 2011, The Annals of thoracic surgery.

[9] J. Barberà,et al. Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry , 2011, Circulation.

[10] M. de Pauw,et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. , 2011, European heart journal.

[11] T. Delhaas,et al. Pediatric Pulmonary Hypertension in the Netherlands: Epidemiology and Characterization During the Period 1991 to 2005 , 2011, Circulation.

[12] L. Sharples,et al. Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial , 2011, The Lancet.

[13] T. Welte,et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.

[14] S. Keshavjee,et al. Impact of extracorporeal life support on outcome in patients with idiopathic pulmonary arterial hypertension awaiting lung transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15] M. Humbert,et al. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease , 2011, European Respiratory Journal.

[16] R. Ewert,et al. Ambrisentan Improves Exercise Capacity and Symptoms in Patients with Portopulmonary Hypertension Ambrisentan verbessert die Belastbarkeit und Symptomatik bei Patienten mit portopulmonaler Hypertonie , 2011 .

[17] J. Wharton,et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. , 2011, Journal of the American College of Cardiology.

[18] Z. Jing,et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[19] J. Grapsa,et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. , 2011, International journal of cardiology.

[20] P. Pellikka,et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. , 2011, Chest.

[21] H. Haller,et al. Osteopontin in patients with idiopathic pulmonary hypertension. , 2011, Chest.

[22] E. Rosenzweig,et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. , 2011, The American journal of cardiology.

[23] Sanjiv J. Shah,et al. Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction , 2011, Circulation. Heart failure.

[24] S. Harikrishnan,et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011 , 2011, Pulmonary circulation.

[25] D. Celermajer,et al. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. , 2011, The Journal of pediatrics.

[26] D. Ivy,et al. Pulmonary arterial hypertension: a comparison between children and adults , 2011, European Respiratory Journal.

[27] A. Torbicki,et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. , 2011, Chest.

[28] M. Madani,et al. Chronic thromboembolic pulmonary hypertension in pediatric patients. , 2011, The Journal of thoracic and cardiovascular surgery.

[29] W. Klepetko,et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[30] L. Stevenson,et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[31] S. Rosenkranz,et al. Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension , 2011, Respiration.

[32] R. Naeije,et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. , 2011, British journal of clinical pharmacology.

[33] Rami Dhillon. The management of neonatal pulmonary hypertension , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[34] M. Humbert,et al. Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? , 2011, Presse medicale.

[35] I. Schulze-Neick,et al. Issues related to the management and therapy of paediatric pulmonary hypertension , 2010, European Respiratory Review.

[36] J. Cracowski,et al. Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies , 2010, The Journal of Rheumatology.

[37] Seung‐Jung Park,et al. Left main coronary artery compression from pulmonary artery enlargement due to pulmonary hypertension: A contemporary review and argument for percutaneous revascularization , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[38] N. Westerhof,et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension , 2010, European Respiratory Journal.

[39] S. Brett,et al. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review , 2010, Critical care.

[40] Takahiro Shiota,et al. Accuracy of right ventricular volumes and function determined by three-dimensional echocardiography in comparison with magnetic resonance imaging: a meta-analysis study. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[41] T. Welte,et al. Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42] A. Chapelier,et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[43] M. Hoeper,et al. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. , 2010, European heart journal.

[44] R. Nishimura,et al. Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[45] Qi Fu,et al. Characterization of Static and Dynamic Left Ventricular Diastolic Function in Patients With Heart Failure With a Preserved Ejection Fraction , 2010, Circulation. Heart failure.

[46] H. Collard,et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[47] H. Heinzl,et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension , 2010, European Respiratory Journal.

[48] M. Humbert,et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. , 2010, European heart journal.

[49] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[50] M. Humbert,et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[51] A. Manes,et al. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.

[52] Horst Olschewski,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.

[53] A. Manes,et al. Effects Of Sildenafil Treatment In Patients With Pulmonary Hypertension Associated With Congenital Cardiac Shunts , 2010, ATS 2010.

[54] K. Iversen,et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. , 2010, European heart journal.

[55] I. Schulze-Neick,et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study , 2010, Heart.

[56] R. Arena,et al. Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[57] L. Shapiro,et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[58] J. Barberà,et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[59] M. Loebe,et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[60] M. Humbert,et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era , 2010, AIDS.

[61] M. Raza. Misclassification of Pulmonary Hypertension Due to Reliance on Pulmonary Capillary Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure , 2010 .

[62] H. Tan,et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. , 2010, The Journal of thoracic and cardiovascular surgery.

[63] N. Lee,et al. Diagnosis and assessment of pulmonary arterial hypertension , 2010 .

[64] Sanjiv J. Shah,et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.

[65] R. Barst,et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study , 2009, British journal of clinical pharmacology.

[66] M. Humbert,et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension , 2009, European Respiratory Journal.

[67] N. Westerhof,et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension , 2009, European Respiratory Journal.

[68] M. Humbert,et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome , 2009, European Respiratory Journal.

[69] J. Newman,et al. Association of the metabolic syndrome with pulmonary venous hypertension. , 2009, Chest.

[70] H. Palevsky,et al. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. , 2009, Mayo Clinic proceedings.

[71] M. Galanski,et al. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital substraction angiography. , 2009, European journal of radiology.

[72] W. Chung,et al. [Genetics and genomics of pulmonary arterial hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[73] M. Maitland,et al. Inflammation, growth factors, and pulmonary vascular remodeling. , 2009, Journal of the American College of Cardiology.

[74] N. Weissmann,et al. Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[75] P. Corris,et al. Interventional and surgical modalities of treatment in pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[76] F. Martinez,et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[77] H. Ghofrani,et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[78] P. Thistlethwaite,et al. Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[79] M. Humbert,et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease , 2009, European Respiratory Journal.

[80] B. Brundage,et al. Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[81] J. Butler,et al. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. , 2009, American heart journal.

[82] M. D. de Vera,et al. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end‐stage liver disease , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[83] Patrick W O'Leary,et al. Measurement, interpretation and use of hemodynamic parameters , 2009, Cardiology in the Young.

[84] H. Tighiouart,et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. , 2009, American journal of respiratory and critical care medicine.

[85] T. Nawrot,et al. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[86] W. Seeger,et al. TRIUMPH 1: Long-Term Safety and Efficacy of Inhaled Treprostinil Sodium in Patients with Pulmonary Arterial Hypertension (PAH) – Two Year Follow-Up. , 2009, ATS 2009.

[87] M. Corretti,et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. , 2009, American journal of respiratory and critical care medicine.

[88] T. Welte,et al. Bridge to Thoracic Organ Transplantation in Patients with Pulmonary Arterial Hypertension Using a Pumpless Lung Assist Device , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89] A Berghold,et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review , 2009, European Respiratory Journal.

[90] M. Beghetti,et al. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[91] M. Humbert,et al. Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension: Results of a Multicenter European Analysis of Pulmonary Artery Pressure Response to Exercise and Hypoxia , 2009, Circulation.

[92] B. Casserly,et al. Ambrisentan for the treatment of pulmonary arterial hypertension , 2008, Drug design, development and therapy.

[93] M. Humbert,et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study , 2008, Rheumatology.

[94] A. Branzi,et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[95] K. Dimopoulos,et al. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? , 2008, European heart journal.

[96] D. Badesch,et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. , 2006, Chest.

[97] W. Auger,et al. Chronic thromboembolic pulmonary hypertension. , 2009, Seminars in respiratory and critical care medicine.

[98] A. Torbicki,et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. , 2008, Journal of the American College of Cardiology.

[99] R. Wiesner,et al. Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[100] S. Stavropoulos,et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. , 2008, Journal of vascular and interventional radiology : JVIR.

[101] T. Fleming,et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (Annals of Internal Medicine (2008) 149 (521-530)) , 2008 .

[102] T. Fleming,et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[103] M. Zenati,et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. , 2008, The Annals of thoracic surgery.

[104] A. Vuylsteke,et al. Successful extracorporeal membrane oxygenation support after pulmonary thromboendarterectomy. , 2008, The Annals of thoracic surgery.

[105] T. Fleming,et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. , 2008, Chest.

[106] Michael Böhm,et al. Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[107] M. Humbert,et al. Portopulmonary hypertension: survival and prognostic factors. , 2008, American journal of respiratory and critical care medicine.

[108] F. Laenger,et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[109] M. Tamm,et al. A randomised, controlled trial of bosentan in severe COPD , 2008, European Respiratory Journal.

[110] S. Nathan,et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. , 2008, Respiratory medicine.

[111] Ashish S Shah,et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. , 2008, The Annals of thoracic surgery.

[112] Piotr Pruszczyk,et al. Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[113] P. Thomas,et al. Biomarkers in pulmonary hypertension , 2008, European Respiratory Journal.

[114] M. Humbert,et al. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[115] J. Trotter,et al. Clinical risk factors for portopulmonary hypertension , 2008, Hepatology.

[116] R. Benza,et al. Guidelines for the prevention of central venous catheter‐related blood stream infections with prostanoid therapy for pulmonary arterial hypertension , 2008, International journal of clinical practice. Supplement.

[117] M. Humbert,et al. Pulmonary Veno-Occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology , 2008, Medicine.

[118] M. Gatzoulis,et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. , 2008, International journal of cardiology.

[119] G. Simonneau,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[120] M. Humbert,et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. , 2008, American journal of respiratory and critical care medicine.

[121] B. Wiens,et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[122] P. Corris,et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[123] M. Olschewski,et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension , 2008, European Respiratory Journal.

[124] N. Westerhof,et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity , 2008, European Respiratory Journal.

[125] E. Hachulla. Effects of Beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled trial. , 2008 .

[126] M. Heneghan,et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[127] M. Manns,et al. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases , 2008, Transplantation.

[128] J. Zwanenburg,et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. , 2008, Journal of the American College of Cardiology.

[129] G. MacGowan,et al. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland , 2008, Heart.

[130] I. Schulze-Neick,et al. Classifying pulmonary hypertension in the setting of the congenitally malformed heart – cleaning up a dog’s dinner , 2008, Cardiology in the Young.

[131] R. Berger,et al. Pulmonary arterial hypertension in congenital cardiac disease – the need for refinement of the Evian-Venice classification , 2008, Cardiology in the Young.

[132] M. Humbert,et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. , 2008, Arthritis and rheumatism.

[133] R. Barst,et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. , 2008, Journal of the American College of Cardiology.

[134] G. Baumann,et al. Long-term follow-up of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension. , 2007, Chest.

[135] Y. Allanore,et al. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials , 2007, Annals of the rheumatic diseases.

[136] M. Mitchell,et al. Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects , 2006, Journal of clinical pharmacology.

[137] G. Simonneau,et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. , 2008, American journal of respiratory and critical care medicine.

[138] J. Barberà,et al. [Standards of care in pulmonary hypertension. Consensus Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)]. , 2008, Archivos de bronconeumologia.

[139] G. Filippatos,et al. [Guidelines on the management of valvular heart disease]. , 2013, Revista espanola de cardiologia.

[140] T. Welte,et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension , 2007, European Respiratory Journal.

[141] R. Barst,et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.

[142] H. Fessler,et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema , 2007, European Respiratory Journal.

[143] W. Seeger,et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension , 2007, European Respiratory Journal.

[144] P. Postmus,et al. Cardiopulmonary Exercise Test Characteristics in Patients with Chronic Obstructive Pulmonary Disease and Associated Pulmonary Hypertension , 2007, Respiration.

[145] K. Dickstein,et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[146] F. Haddad,et al. Management strategies for patients with pulmonary hypertension in the intensive care unit* , 2007, Critical care medicine.

[147] P. Engelfriet,et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. , 2007, International journal of cardiology.

[148] M. Rubens,et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. , 2007, Journal of the American College of Cardiology.

[149] M. Humbert,et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension , 2007, European Respiratory Journal.

[150] R. Gerszten,et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007, Circulation.

[151] J. McMurray,et al. An epidemiological study of pulmonary arterial hypertension , 2007, European Respiratory Journal.

[152] M. Humbert,et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. , 2007, Human pathology.

[153] R. Barst,et al. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease , 2007, Annals of the rheumatic diseases.

[154] T. Welte,et al. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension , 2007, European Respiratory Journal.

[155] M. Remy-Jardin,et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. , 2007, The Journal of rheumatology.

[156] A. Torbicki. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. , 2007, European heart journal.

[157] G. Klintmalm,et al. The Impact of Treatment of Portopulmonary Hypertension on Survival Following Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[158] J. E. Cotes,et al. Recommendations on the use of exercise testing in clinical practice , 2007, European Respiratory Journal.

[159] P. Gishen,et al. Ventilation–Perfusion Scintigraphy Is More Sensitive than Multidetector CTPA in Detecting Chronic Thromboembolic Pulmonary Disease as a Treatable Cause of Pulmonary Hypertension , 2007, Journal of Nuclear Medicine.

[160] J. Bronzwaer,et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. , 2007, European heart journal.

[161] Grzegorz Opolski,et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. , 2007, Chest.

[162] M. Humbert,et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[163] W. Seeger,et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study , 2007, European Respiratory Journal.

[164] W. Klepetko,et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension , 2007, Journal of thrombosis and haemostasis : JTH.

[165] R. Oudiz. Pulmonary hypertension associated with left-sided heart disease. , 2007, Clinics in chest medicine.

[166] H. Collard,et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. , 2007, Chest.

[167] A. Zaiman,et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension , 2007, European Respiratory Journal.

[168] G. Diller,et al. Pulmonary Vascular Disease in Adults With Congenital Heart Disease , 2007, Circulation.

[169] B. Hartmann,et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. , 2007, Chest.

[170] M. Humbert,et al. Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension , 2007, Journal of cardiovascular pharmacology.

[171] Helmut Baumgartner,et al. Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology , 2007 .

[172] K. Kerr,et al. Chronic thromboembolic pulmonary hypertension. , 2001, Clinics in chest medicine.

[173] M. Hoeper,et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. , 2007, American heart journal.

[174] Z. Jing,et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. , 2006, Journal of the American College of Cardiology.

[175] P. Engelfriet,et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease , 2006, Heart.

[176] R. Barst,et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil , 2006, European Respiratory Journal.

[177] W. Schmidt,et al. Sildenafil improves hemodynamic parameters in COPD--an investigation of six patients. , 2006, Pulmonary pharmacology & therapeutics.

[178] P. Thistlethwaite,et al. Venovenous extracorporeal life support after pulmonary endarterectomy: indications, techniques, and outcomes. , 2006, The Annals of thoracic surgery.

[179] R. Wiesner,et al. Portopulmonary hypertension: Results from a 10‐year screening algorithm , 2006, Hepatology.

[180] R. Barst,et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[181] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[182] T. Abraham,et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[183] A. Lammers,et al. Epoprostenol treatment in children with severe pulmonary hypertension , 2006, Heart.

[184] M. Gupta,et al. Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome: A Preliminary Observational Study , 2006, Circulation.

[185] F. Herth,et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension , 2006, Circulation.

[186] M. Hoeper,et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.

[187] F. Fallani,et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[188] Nazzareno Galiè,et al. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. , 2006, Proceedings of the American Thoracic Society.

[189] W. Klepetko,et al. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. , 2006, Proceedings of the American Thoracic Society.

[190] J. Krishnan,et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. , 2006, Arthritis and rheumatism.

[191] W. Seeger,et al. Sildenafil treatment for portopulmonary hypertension , 2006, European Respiratory Journal.

[192] T. Ueland,et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. , 2006, The American journal of cardiology.

[193] Marshall I Hertz,et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[194] M. Gatzoulis,et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. , 2006, Journal of the American College of Cardiology.

[195] G. Barbarini,et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension , 2006, Heart.

[196] M. Gatzoulis,et al. Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study , 2006, Circulation.

[197] A. Nicholson,et al. Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis: A Clinicopathologic Study of 35 Cases , 2006, The American journal of surgical pathology.

[198] M. Humbert,et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study , 2006, European Respiratory Journal.

[199] M. Gómez-Sánchez,et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. , 2006, Chest.

[200] C. Denton,et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[201] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.

[202] M. Humbert,et al. Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[203] B. Madden,et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. , 2006, Vascular pharmacology.

[204] R. Souza,et al. [Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo]. , 2006, Revista da Associacao Medica Brasileira.

[205] A. Torbicki,et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[206] N. Panay,et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension , 2006, Journal of Family Planning and Reproductive Health Care.

[207] S. Nathan,et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[208] R. Benza,et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. , 2006, Chest.

[209] M. Humbert,et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. , 2006, European heart journal.

[210] J. Carlquist,et al. Mutations of the TGF‐β type II receptor BMPR2 in pulmonary arterial hypertension , 2006, Human mutation.

[211] M. Humbert,et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease , 2006, European Respiratory Journal.

[212] M. Humbert,et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension , 2006, European Respiratory Journal.

[213] J. Loscalzo,et al. Pulmonary arterial hypertension. , 2004, Annals of medicine.

[214] F. Martinez,et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[215] Marshall I Hertz,et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[216] M. Humbert,et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.

[217] J. E. Hansen,et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. , 2006, The American journal of cardiology.

[218] M. Humbert,et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[219] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[220] G. Derrick,et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension , 2005, Heart.

[221] M. Kramer,et al. Pregnancy Outcome in Patients With Pulmonary Arterial Hypertension Receiving Prostacyclin Therapy , 2005, Obstetrics and gynecology.

[222] T. Welte,et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.

[223] J. Hankinson,et al. Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[224] P. Brillet,et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity , 2005, European Respiratory Journal.

[225] F. López-Ríos,et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure , 2005, European journal of heart failure.

[226] R. Barst,et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. , 2005, Chest.

[227] T. Welte,et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.

[228] Steven H Abman,et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[229] P. Poole‐Wilson,et al. Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication , 2005, Circulation.

[230] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[231] P. Chang,et al. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[232] J. Parameshwar,et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension , 2005, Thorax.

[233] N. Morrell,et al. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease , 2005, Respiratory research.

[234] M. Humbert,et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol , 2005, Thorax.

[235] A. Chaouat,et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[236] A. Boobis,et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. , 2005, British journal of clinical pharmacology.

[237] J. Wharton,et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.

[238] D. Fliser,et al. Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[239] D. Stephens,et al. Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study , 2005, Circulation.

[240] W. Seeger,et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[241] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[242] D. Benhamou,et al. Severe Pulmonary Hypertension during Pregnancy: Mode of Delivery and Anesthetic Management of 15 Consecutive Cases , 2005, Anesthesiology.

[243] R. Barst,et al. Erratum: "Survival with first-line bosentan in patients with primary pulmonary hypertension" (European Respiratory Journal (2005) vol. 25 (244-249)) , 2005 .

[244] H. Mal,et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. , 2005, Chest.

[245] M. de la Morena,et al. Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. , 2005, The Journal of thoracic and cardiovascular surgery.

[246] M. Hoeper,et al. Bosentan therapy for portopulmonary hypertension , 2005, European Respiratory Journal.

[247] D. DeMets,et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. , 2005, Journal of cardiac failure.

[248] R. Barst,et al. Survival with first-line bosentan in patients with primary pulmonary hypertension , 2005, European Respiratory Journal.

[249] W. Hopkins. The remarkable right ventricle of patients with Eisenmenger syndrome , 2005, Coronary artery disease.

[250] Thomas R Fleming,et al. Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.

[251] E. Fiumana,et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells , 2005, Basic Research in Cardiology.

[252] M. Humbert,et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[253] T. Welte,et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension , 2004, European Respiratory Journal.

[254] B. Löwe,et al. Anxiety and Depression in Patients With Pulmonary Hypertension , 2004, Psychosomatic medicine.

[255] W. Seeger,et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.

[256] G. Aurigemma,et al. Diastolic heart failure , 2004 .

[257] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[258] G. Konduri. New approaches for persistent pulmonary hypertension of newborn. , 2004, Clinics in perinatology.

[259] S. Rich,et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.

[260] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[261] M. Humbert,et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. , 2004, AJR. American journal of roentgenology.

[262] D. Mccrory,et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[263] A. Torbicki,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[264] P. Corris,et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[265] M. Humbert,et al. Pathologic assessment of vasculopathies in pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[266] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[267] J. Krishnan,et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[268] I. Lang. Chronic thromboembolic pulmonary hypertension--not so rare after all. , 2004, The New England journal of medicine.

[269] Paolo Prandoni,et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[270] B. Raju,et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[271] R. D. du Bois,et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. , 2004, Rheumatology.

[272] K. Kerr,et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension , 2004, European Respiratory Journal.

[273] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[274] D. Bonnet,et al. Potts shunt in patients with pulmonary hypertension. , 2004, The New England journal of medicine.

[275] A. Branzi,et al. The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.

[276] W. Seeger,et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension , 2004, European Respiratory Journal.

[277] D. Tsikas,et al. Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans , 2004, Circulation.

[278] Desa. The former Yugoslav Republic of Macedonia , 2004, Constitutions of Europe (2 vols.).

[279] G. Aurigemma,et al. Clinical practice. Diastolic heart failure. , 2004, The New England journal of medicine.

[280] R. Barst,et al. Pulmonary arterial hypertension in children , 2004, Pediatric pulmonology.

[281] C. Denton,et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[282] S. Archer,et al. Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension , 2003, Circulation.

[283] E. Fadel,et al. Polymorphism of the Serotonin Transporter Gene and Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease , 2003, Circulation.

[284] M. Mcgoon,et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. , 2003, Mayo Clinic proceedings.

[285] A. Torbicki,et al. Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.

[286] M. Hoeper,et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids , 2003, European Respiratory Journal.

[287] W. Seeger,et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[288] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[289] M. Humbert,et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.

[290] R. Ross,et al. ATS/ACCP statement on cardiopulmonary exercise testing. , 2003, American journal of respiratory and critical care medicine.

[291] H. Kauczor,et al. Value of contrast-enhanced MR angiography and helical CT angiography in chronic thromboembolic pulmonary hypertension , 2003, European Radiology.

[292] W. Seeger,et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[293] Miguel. Sánchez,et al. Tratamiento de la hipertensión pulmonar asociada a la infección por VIH con treprostinil , 2003 .

[294] R. Barst,et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.

[295] J. E. Hansen,et al. Pulmonary function in primary pulmonary hypertension. , 2003, Journal of the American College of Cardiology.

[296] J. Newman,et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. , 2003, American journal of respiratory and critical care medicine.

[297] M. Sutton,et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[298] M. Ando,et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. , 2003, Chest.

[299] R. Hetzer,et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. , 2003, European heart journal.

[300] S. Kimmel,et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.

[301] A. Branzi,et al. Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[302] P. Escribano Subías,et al. [Treatment of HIV-associated pulmonary hypertension with treprostinil]. , 2003, Revista espanola de cardiologia.

[303] P. Kao,et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. , 2002, Chest.

[304] A. Coats,et al. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? , 2002, International journal of cardiology.

[305] R. Favaloro,et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. , 2002, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[306] W. Seeger,et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[307] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[308] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[309] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[310] C. Lavie,et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. , 2002, Circulation.

[311] R. Hetzer,et al. Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.

[312] S. Keshavjee,et al. Heart-lung or lung transplantation for Eisenmenger syndrome. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[313] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[314] G. Koch,et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[315] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[316] M. Humbert,et al. Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[317] M. Rubenfire,et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[318] M. Krowka. Hepatopulmonary syndrome and portopulmonary hypertension , 2001, Current treatment options in cardiovascular medicine.

[319] M. Humbert,et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[320] M. Gladwin,et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease , 2002, Nature Medicine.

[321] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[322] ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[323] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[324] Arthur E. Weyman,et al. Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects , 2001, Circulation.

[325] J. Cohn. Optimal diuretic therapy for heart failure. , 2001, The American journal of medicine.

[326] G. Castro. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[327] J. Sandoval,et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. , 2001, American journal of respiratory and critical care medicine.

[328] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.

[329] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[330] J. Cigarroa,et al. Relation of pulmonary arterial diastolic and mean pulmonary arterial wedge pressures in patients with and without pulmonary hypertension. , 2001, The American journal of cardiology.

[331] M. Humbert,et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. , 2001, Clinics in chest medicine.

[332] A. Arroliga,et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. , 2001, Chest.

[333] M. Humbert,et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[334] J. E. Hansen,et al. Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[335] A. Chaouat,et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. , 2001, American journal of respiratory and critical care medicine.

[336] M. Rubenfire,et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. , 2001, The European respiratory journal.

[337] K. Bremme,et al. Cesarean section under epidural ropivacaine 0.75% in a parturient with severe pulmonary hypertension , 2001, Acta anaesthesiologica Scandinavica.

[338] J. Feinstein,et al. Balloon Pulmonary Angioplasty for Treatment of Chronic Thromboembolic Pulmonary Hypertension , 2001, Circulation.

[339] L. Tavazzi,et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[340] J. Higenbottam. Recommendations on the management of pulmonary hypertension in clinical practice. , 2001, Heart.

[341] E. Ely,et al. Pulmonary veno-occlusive disease: a case series and new observations. , 2000, Chest.

[342] W. Colucci,et al. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[343] K. Kangawa,et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[344] R. Wiesner,et al. Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[345] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[346] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[347] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .

[348] W. Seeger,et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.

[349] B. Groves,et al. Hyperuricemia in severe pulmonary hypertension. , 2000, Chest.

[350] R. Wiesner,et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.

[351] M. Uematsu,et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[352] J. Hohlfeld,et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[353] W. Seeger,et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.

[354] R. Salamon,et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[355] Thomas Albrecht,et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent , 1999, The Lancet.

[356] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[357] G. Maislin,et al. Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[358] M. Koss,et al. Pulmonary veno-occlusive disease. , 1996, Current opinion in pulmonary medicine.

[359] E. Weitzenblum,et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[360] M. Hoeper,et al. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. , 1998, The European respiratory journal.

[361] P. Presbitero,et al. Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.

[362] S. Rich,et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. , 1998, Chest.

[363] L. Sharples,et al. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[364] J. Sandoval,et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.

[365] M. Estenne,et al. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[366] R. Kuzo,et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. , 1998, Chest.

[367] M. Humbert,et al. Pulmonary vascular disorders in portal hypertension. , 1998, The European respiratory journal.

[368] J B Seward,et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.

[369] M. Humbert,et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.

[370] C. Howell,et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.

[371] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[372] S. Lévy,et al. Long-term effects of cicletanine on secondary pulmonary hypertension. , 1996, Journal of cardiovascular pharmacology.

[373] S. Swensen,et al. Mosaic pattern of lung attenuation on CT scans: frequency among patients with pulmonary artery hypertension of different causes. , 1997, AJR. American journal of roentgenology.

[374] F. Harrell,et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[375] R. Speich,et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.

[376] C. Howell,et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.

[377] A J Tajik,et al. Doppler echocardiographic index for assessment of global right ventricular function. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[378] J. Murray,et al. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger's physiology. , 1996, Journal of clinical anesthesia.

[379] J. Barberà,et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease , 1996, The Lancet.

[380] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[381] K. Segerberg. To do and not to do. , 1996 .

[382] E. Trulock,et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[383] D. Driscoll,et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. , 1995, Circulation.

[384] C. Benjamin,et al. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.

[385] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[386] M. Humbert,et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[387] A. Chaouat,et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. , 1995, Chest.

[388] A. Branzi,et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. , 1995, The American journal of cardiology.

[389] S. Rich,et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. , 1995, Chest.

[390] M. B. Perryman,et al. Importance of angiotensin-converting enzyme in pulmonary hypertension. , 1995, Cardiology.

[391] K. Huber,et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. , 1994, American journal of respiratory and critical care medicine.

[392] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[393] C. Mélot,et al. Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise. , 1993, Journal of applied physiology.

[394] R. MacMillan. Cardiac magnetic resonance imaging. , 1993, Cardiovascular clinics.

[395] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[396] L. Mestroni,et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. , 1992, The Journal of clinical investigation.

[397] A Costard-Jäckle,et al. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. , 1992, Journal of the American College of Cardiology.

[398] J. Moller,et al. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. , 1991, The American journal of cardiology.

[399] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[400] T. Evans,et al. Adenosine as a Vasodilator in Primary Pulmonary Hypertension , 1991, Circulation.

[401] D. Stewart,et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[402] D. Moodie,et al. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. , 1991, Journal of the American College of Cardiology.

[403] J. H. Diehl,et al. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .

[404] A. Peacock. Pulmonary hypertension due to chronic hypoxia. , 1990, BMJ.

[405] J. Barberà,et al. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. , 1990, Chest.

[406] N. Reichek,et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. , 1989, Circulation.

[407] F. Philip-Joet,et al. Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. , 1988, The European respiratory journal.

[408] J. Rouleau,et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.

[409] D. Buff. Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[410] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[411] B. Brundage,et al. Antinuclear antibodies in primary pulmonary hypertension. , 1986, Journal of the American College of Cardiology.

[412] W. Mckenna,et al. Echocardiographic measurement of the normal adult right ventricle , 1986 .

[413] C. Oakley,et al. Factors that influence the outcome of primary pulmonary hypertension. , 1986, British heart journal.

[414] G. Gregoratos,et al. Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction. , 1985, Annals of internal medicine.

[415] E. Weitzenblum,et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. , 1985, The American review of respiratory disease.

[416] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[417] G. Simonneau,et al. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. , 1981, The New England journal of medicine.

[418] M. Gee,et al. Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep. , 1981, The American journal of physiology.

[419] C. Kittle,et al. Pulmonary venoocclusive disease. , 1976, The Annals of thoracic surgery.